Asad Haider
Stock Analyst at Goldman Sachs
(2.79)
# 1,645
Out of 5,182 analysts
15
Total ratings
71.43%
Success rate
17.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Upgrades: Buy | $115 → $142 | $96.70 | +46.85% | 2 | Jan 16, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $213 → $240 | $237.96 | +0.86% | 3 | Dec 19, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Neutral | $30 → $37 | $36.25 | +2.07% | 2 | Dec 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $51 → $57 | $58.06 | -1.83% | 2 | Dec 2, 2025 | |
| INVA Innoviva | Initiates: Sell | $17 | $23.97 | -29.08% | 1 | Sep 30, 2025 | |
| RPRX Royalty Pharma | Initiates: Buy | $42 | $48.43 | -13.28% | 1 | Sep 30, 2025 | |
| PCVX Vaxcyte | Initiates: Neutral | $38 | $61.75 | -38.46% | 1 | Sep 12, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $929.55 | -4.47% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $206.47 | -6.04% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $27.34 | -8.56% | 1 | Apr 8, 2025 |
BioNTech SE
Jan 16, 2026
Upgrades: Buy
Price Target: $115 → $142
Current: $96.70
Upside: +46.85%
Johnson & Johnson
Dec 19, 2025
Maintains: Buy
Price Target: $213 → $240
Current: $237.96
Upside: +0.86%
NewAmsterdam Pharma Company
Dec 2, 2025
Maintains: Neutral
Price Target: $30 → $37
Current: $36.25
Upside: +2.07%
Bristol-Myers Squibb Company
Dec 2, 2025
Maintains: Neutral
Price Target: $51 → $57
Current: $58.06
Upside: -1.83%
Innoviva
Sep 30, 2025
Initiates: Sell
Price Target: $17
Current: $23.97
Upside: -29.08%
Royalty Pharma
Sep 30, 2025
Initiates: Buy
Price Target: $42
Current: $48.43
Upside: -13.28%
Vaxcyte
Sep 12, 2025
Initiates: Neutral
Price Target: $38
Current: $61.75
Upside: -38.46%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $929.55
Upside: -4.47%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $206.47
Upside: -6.04%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $27.34
Upside: -8.56%